This information was published, 2017-02-14 07:53 CET (GLOBE NEWSWIRE) --
“This is the first time the company obtains a granted patent in China. It is a step forward in Episurf’s efforts of securing intellectual property protection globally” comments Pål Ryfors, acting CEO of Episurf Medical.
For more information, please contact:
Pål Ryfors, acting CEO, Episurf Medical
Tel: +46 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above.
